imatinib mesylate has been researched along with Chronic Fatigue and Immune Dysfunction Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alimena, G; Baccarani, M; Baratè, C; Bergamaschi, M; Breccia, M; Cottone, F; Dabusti, M; Deliliers, GL; Di Lorenzo, R; Efficace, F; Fava, C; Leoni, P; Levato, L; Luciano, L; Mandelli, F; Martino, B; Rambaldi, A; Rosti, G; Sica, S; Simula, MP; Specchia, G; Stagno, F; Turri, D; Veneri, D; Vignetti, M | 1 |
1 other study(ies) available for imatinib mesylate and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Fatigue Syndrome, Chronic; Female; Health Surveys; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Muscle Cramp; Musculoskeletal Pain; Piperazines; Pyrimidines; Quality of Life; Social Behavior; Young Adult | 2013 |